MRM
MEDIROM Healthcare Technologies Inc. Consumer Cyclical - Personal Services Investor Relations →
MEDIROM Healthcare Technologies Inc. (MRM) closed at $1.25 as of 2026-03-20, trading 69.4% below its 200-week moving average of $4.08. This places MRM in the extreme value zone. The stock is currently moving closer to the line, down from -69.3% last week. With a 14-week RSI of 10, MRM is in oversold territory.
Over the past 14 weeks, down-weeks have had more trading volume than up-weeks (0.16 buyers-vs-sellers ratio). That means when people are active, they're more often selling than buying. Sellers are still more in control than buyers.
Over the past 224 weeks of data, MRM has crossed below its 200-week moving average 1 time. On average, these episodes lasted 224 weeks.
With a market cap of $10 million, MRM is a small-cap stock. The company generates a free cash flow yield of 3164.1%, which is notably high. Return on equity stands at 53.2%, indicating strong profitability. The stock trades at 6.4x book value.
Share count has increased 61.8% over three years, indicating dilution.
Over the past 4.3 years, a hypothetical investment of $100 in MRM would have grown to $21, compared to $145 for the S&P 500. MRM has returned -30.5% annualized vs 9.0% for the index, underperforming the broader market over this period.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: MRM vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After MRM Crosses Below the Line?
Across 1 historical episodes, buying MRM when it crossed below its 200-week moving average produced an average return of -25.0% after 12 months (median -25.0%), compared to -18.0% for the S&P 500 over the same periods. After 24 months, the average return was -6.0% vs +3.0% for the index.
Each line shows $100 invested at the moment MRM crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
MRM has crossed below its 200-week MA 1 time
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Dec 2021 | Ongoing | 224+ | 93.6% | Ongoing | -82.6% |
Frequently Asked Questions
Is MRM below its 200-week moving average?
Yes. As of 2026-03-20, MEDIROM Healthcare Technologies Inc. (MRM) is trading 69.4% below its 200-week moving average of $4.08. The current price is $1.25.
What is MRM's 200-week moving average price?
MEDIROM Healthcare Technologies Inc.'s 200-week moving average is $4.08 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when MRM drops below its 200-week moving average?
MRM has crossed below its 200-week moving average 1 time in our data. These episodes lasted 224 weeks on average.
Is MRM a good value right now?
Here's what our data says about MRM as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 10 (oversold). Free cash flow yield is 3164.1%. Return on equity is 53.2%. Price-to-book is 6.4x. This is not a buy or sell recommendation — always do your own research.
How does MRM compare to the S&P 500?
Over the past 4.3 years, $100 invested in MRM would have grown to $21, compared to $145 for the S&P 500. That's -30.5% annualized vs 9.0% for the index. MRM has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20